Interferon-modulated vaccines against HIV
$222,322DP2FY2021DANIH
Northwestern University At Chicago, Evanston IL
Investigators
Linked publications & trials
Paper 39432667Paper 39186606Paper 39007643Paper 38861331Paper 38822334Paper 38496467Paper 38106001Paper 37313412Paper 37090595Paper 36992700Paper 36857186Paper 36219482Paper 35958615Paper 35794898Paper 34943952Paper 34761549Paper 34648369Paper 34623973Paper 34450033Paper 33907732Paper 33821275Paper 32820330
Abstract
PROJECT SUMMARY We have elucidated a strategy to improve viral vaccines by combining IFN-I receptor antibodies with the vaccine. Our data show that this approach improves the efficacy of multiple viral vaccines, including the clinically approved yellow fever vaccine and experimental HIV vaccines in mice. Such data provide impetus for testing whether IFN- modulation can also improve the efficacy of HIV vaccines in primates and humanized mice challenged intravenously with HIV. These data are potentially translatable to humans, since there is a similar antibody that has undergone extensive clinical testing in humans to block IFN-I (Anifrolumab).
View original record on NIH RePORTER →